Zolpidem: Efficacy and Side Effects for Insomnia
Purpose of Review
Insomnia is a common type of sleep disorder defined by an ongoing difficulty initiating or maintaining sleep or nonrestorative sleep with subsequent daytime impairment. The sleep disturbances in insomnia usually manifest as difficulty in falling asleep, maintaining the continuity of sleep, or waking up too early in the morning well before the desired time, irrespective of the adequate circumstances to sleep every night. Insomnia can significantly impact daytime functioning resulting in decreased workplace productivity, proneness to errors and accidents, inability to concentrate, frequent daytime naps, and poor quality of life.
The treatment of insomnia should involve a multi-disciplinary approach, focusing on implementing behavioral interventions, improving sleep hygiene, managing psychological stressors, hypnotic treatment, and pharmacological therapy. The most effective therapies utilize cognitive behavioral therapy in conjunction with pharmacotherapy to minimize the needed dose and any resulting side effects. Non-benzodiazepine hypnotics such as zolpidem, eszopiclone, zaleplon are the most used as adjunctive treatment. One of the most used of these hypnotics is zolpidem. However, zolpidem has a wide variety of adverse effects and has some special considerations noted in the literature.
Recent Findings
Zolpidem has been associated with an increased risk of falls in hospitalized patients with an OR of 4.28 (P <0.001) when prescribed short-term for insomnia. The relative risk (RR) for hip fractures in patients taking zolpidem was described as 1.92 (95% CI 1.65-2.24; P<0.001), with hip fractures being the most commonly seen. A case series of 119 inpatients aged 50 or older demonstrated that a majority (80.8%) of ADRs were central nervous system (CNS)-related such as confusion, dizziness, and daytime sleepiness. A systematic review of 24 previous studies of sleepwalking associated with zolpidem demonstrated that the association was not dependent on age, dose, medical history, or even a history of sleepwalking at any time before zolpidem use. Suicide attempts and completion have been successfully linked with zolpidem use (OR 2.08; 95% CI 1.83-2.63) in patients regardless of the presence of comorbid psychiatric illness. There have been multiple cases reported of seizures following the withdrawal of zolpidem. Most cases have demonstrated that withdrawal seizures occurred in patients taking daily dosages of around 450-600mg/day, but some reported them as low as 160mg/day. Rebound insomnia has been a concern to prescribers of zolpidem. Sleep onset latency has been demonstrated to be significantly increased on the first night after stopping zolpidem (13.0 minutes; 95% CI 4.3-21.7; P<0.01). Women had a non-significantly higher mean plasma concentration than men after 8 hours for the 10mg IR (28 vs. 20 ng/mL) and the 12.5mg MR (33 vs. 28ng/mL). The FDA has classified zolpidem as a category C drug based on adverse outcomes seen in animal fetal development. In the mothers exposed to zolpidem, there was an increased incidence of low birth weight (OR = 1.39; P<0.001), preterm delivery (OR 1.49; P<0.001), small for gestational age (SGA) babies (OR = 1.34; P<0.001), and cesarean deliveries (OR =1.74; P<0.001). The rate of congenital abnormalities was not significantly increased with zolpidem (0.48 vs 0.65%; P = 0.329).
Summary
Insomnia is linked to fatigue, distractibility, mood instability, decreased satisfaction, and overall decreased quality of life. Optimal therapy can aid patients in returning to baseline and increase their quality of life. Zolpidem is a helpful drug for the treatment of insomnia in conjunction with cognitive-behavioral therapy. When prescribed to elderly patients, the dose should be adjusted to account for their slower drug metabolism. Still, zolpidem is considered a reasonable choice of therapy because it has a lower incidence of residual daytime sleepiness and risk of falls when compared to other drugs. The most concerning adverse effects, which are often the most publicized, include the complex behaviors that have been seen in patients taking Zolpidem, such as sleeping, hallucinations, increased suicidality, driving cars while asleep, and even a few cases of committing homicide. Even so, zolpidem could be a suitable pharmacological treatment for insomnia. Decisions for whether or not to prescribe it and the dosage should be made on a case-by-case basis, considering both the psychical and psychiatric risks posed to the patient with insomnia versus if the patient were to take zolpidem to treat their condition.
1. Burman D. Sleep Disorders: Insomnia. FP Essent.2017;460:22-28.
2. Schutte-Rodin SL, Broch L, Buysee D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. Journal of Clinical Sleep Medicine.2008;4(5):487-504. doi:10.5664/jcsm.27286
3. Patel D, Steinberg J, Patel P. Insomnia in the elderly: A review. Journal of Clinical Sleep Medicine.2018;14(6):1017-1024. doi:10.5664/jcsm.7172
4. Riemann D, Nissen C, Palagini L, Otte A, Perlis ML, Spiegelhalder K. The neurobiology, investigation, and treatment of chronic insomnia. The Lancet Neurology. Published online 2015. doi:10.1016/S1474-4422(15)00021-6
5. Morin CM, Drake CL, Harvey AG, et al. Article number: 15026 NATURE REVIEWS| DISEASE PRIMERS VOLUME. Nature Publishing Group. Published online 2015. doi:10.1038/nrdp.2015.26
6. Kaur H, Bollu PC. Insomnia, Chronic.;2018.
7. Ohayon MM. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Medicine Reviews. Published online 2002. doi:10.1053/smrv.2002.0186
8. Cunnington D, Junge MF, Fernando AT. Insomnia: Prevalence, consequences and effective treatment. Medical Journal of Australia. Published online 2013. doi:10.5694/mja13.10718
9. Maness DL, Khan M. Nonpharmacologic management of chronic insomnia. American Family Physician.2016;92(12):1058-1064.
10. Kaye-Stacey M, Attarian H. Advances in the management of chronic insomnia. BMJ (Online).2016;354. doi:10.1136/bmj.i2123
11. Bragg S, Benich JJ, Christian N, Visserman J, Freedy J. Updates in insomnia diagnosis and treatment. The International Journal of Psychiatry in Medicine.2019;54(5):275-289. doi:10.1177/0091217419860716
12. Trauer JM, Qian MY, Doyle JS, Shantha, Rajaratnam MW, Cunnington D. Cognitive behavioral therapy for chronic insomnia: A systematic review and meta-analysis. Annals of Internal Medicine.2015;163:191-204. doi:10.7326/M14-2841
13. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: A randomized controlled trial. Journal of the American Medical Association.2006;295(24):2851-2858. doi:10.1001/jama.295.24.2851
14. Wu R, Bao J, Zhang C, Deng J, Long C. Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia. Psychotherapy and Psychosomatics.2006;75(4):220-228. doi:10.1159/000092892
15. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: A randomized controlled trial and direct comparison. Archives of Internal Medicine.2004;164(17):1888-1896. doi:10.1001/archinte.164.17.1888
16. Omvik S, Sivertsen B, Pallesen S, Bjorvatn B, Havik OE, Nordhus IH. Daytime functioning in older patients suffering from chronic insomnia: Treatment outcome in a randomized controlled trial comparing CBT with Zopiclone. Behaviour Research and Therapy.2008;46(5):623-641. doi:10.1016/j.brat.2008.02.013
17. McClusky HY, Milby JB, Switzer PK, Williams V, Wooten V. Efficacy of behavioral versus triazolam treatment in persistent sleep-onset insomnia. American Journal of Psychiatry. 1991;148(1):121-126. doi:10.1176/ajp.148.1.121
18. Hintze JP, Edinger JD. Hypnotic discontinuation in chronic insomnia. Sleep Medicine Clinics.2018;13(2):263-270. doi:10.1016/j.jsmc.2018.02.008
19. Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study. Sleep.2013;36(2):189-196. doi:10.5665/sleep.2370
20. Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant. Neurology.2012;79(23):2265-2274. doi:10.1212/WNL.0b013e31827688ee
21. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLoS ONE.2013;8(5):63773. doi:10.1371/journal.pone.0063773
22. Zolpidem Uses, Dosage & Side Effects - Drugs.com.
23. FDA. Zolpidem Prescribing and Safety Information. Published 2007. Accessed October 11, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019908s027lbl.pdf
24. Sanger DJ, Depoortere H. The Pharmacology and Mechanism of Action of Zolpidem. CNS Drug Reviews.1998;4(4):323-340. doi:10.1111/j.1527-3458.1998.tb00074.x
25. PubChem Compound Summary for CID 5732, Zolpidem. National Center for Biotechnology Information.
26. Drover D, Lemmens H, Naidu S, Cevallos W, Darwish M, Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clinical Therapeutics. Published online 2000. doi:10.1016/S0149-2918(00)83043-X
27. Salva P, Costa J. Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem. Clinical Pharmacokinetics. Published online 1995. doi:10.2165/00003088-199529030-00002
28. Byeon JY, Kim YH, Kim SH, et al. The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Archives of Pharmacal Research. Published online 2018. doi:10.1007/s12272-018-1070-y
29. Olubodun JO, Ochs HR, Von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: Possible modulation by testosterone in men. British Journal of Clinical Pharmacology. Published online 2003. doi:10.1046/j.0306-5251.2003.01852.x
30. Westermeyer J, Carr TM. Zolpidem-associated consequences: An updated literature review with case reports. Journal of Nervous and Mental Disease.2020;208(1):28-32. doi:10.1097/NMD.0000000000001074
31. Gillis CM, Poyant JO, Degrado JR, Ye L, Anger KE, Owens RL. Inpatient pharmacological sleep aid utilization is common at a tertiary medical center. Journal of Hospital Medicine.2014;9(10):652-657. doi:10.1002/jhm.2246
32. Park SM, Ryu J, Lee DR, Shin D, Yun JM, Lee J. Zolpidem use and risk of fractures: A systematic review and meta-analysis. Osteoporosis International.2016;27(10):2935-2944. doi:10.1007/s00198-016-3605-8
33. Treves N, Perlman A, Geron LK, Asaly A, Matok I. Z-drugs and risk for falls and fractures in older adults - a systematic review and meta-analysis. Age and Ageing.2018;47(2):201-208. doi:10.1093/ageing/a fx167
34. Andrade C. Sedative hypnotics and the risk of falls and fractures in the elderly. Journal of Clinical Psychiatry.2018;79(3). doi:10.4088/JCP.18f12340
35. Stranks EK, Crowe SF. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: A systematic review and meta-analysis. Journal of Clinical and Experimental Neuropsychology.2014;36(7):691-700. doi:10.1080/13803395.2014.928268
36. Ito SU, Kanbayashi T, Takemura T, et al. Acute effects of zolpidem on daytime alertness, psychomotor and physical performance. Neuroscience Research.2007;59(3):309-313. doi:10.1016/j.neures.2007.07.009
37. Mahoney JE, Webb MJ, Gray SL. Zolpidem prescribing and adverse drug reactions in hospitalized general medicine patients at a veterans affairs hospital. American Journal Geriatric Pharmacotherapy.2004;2(1):66-74. doi:10.1016/S1543-5946(04)90008-6
38. McMahon M. Zolpidem, complex sleep-related behaviour and volition. Journal of Law, Medicine, and Ethics.2016;24(2):455-477.
39. Australian Government Department of Health Therapeutic Goods Administration. Zolpidem ('Stilnox') | Therapeutic Goods Administration (TGA). Accessed October 11, 2020. https://www.tga.gov.au/alert/zolpidem-stilnox
40. Wong CK, Marshall NS, Grunstein RR, et al. Spontaneous adverse event reports associated with zolpidem in the United States 2003-2012. Journal of Clinical Sleep Medicine.2017;13(2):223-234. doi:10.5664/jcsm.6452
41. Stallman HM, Kohler M, White J. Medication induced sleepwalking: A systematic review. Sleep Medicine Reviews.2018;37:105-113. doi:10.1016/j.smr v.2017.01.005
42. Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH. Association between zolpidem and suicide: A nationwide population-based case-control study. Mayo Clinic Proceedings.2016;91(3):308-315. doi:10.1016/j.mayocp.2015.10.022
43. Schifano F, Chiappini S, Corkery JM, Guirguis A. An insight into z-drug abuse and dependence: An examination of reports to the European medicines agency database of suspected adverse drug reactions. International Journal of Neuropsychopharmacology.2019;22(4):270-277. doi:10.1093/ijnp/pyz007
44. Chiaro G, Castelnovo A, Bianco G, Maffei P, Manconi M. Severe chronic abuse of zolpidem in refractory insomnia. Journal of Clinical Sleep Medicine.2018;14(7):1257-1259. doi:10.5664/jcsm.7240
45. Victorri-Vigneau C, Gérardin M, Rousselet M, Guerlais M, Grall-Bronnec M, Jolliet P. An update on zolpidem abuse and dependence. Journal of Addictive Diseases.2014;33(1):15-23. doi:10.1080/10550887.2014.882725
46. Licata SC, Mashhoon Y, MacLean RR, Lukas SE. Modest abuse-related subjective effects of zolpidem in drug-naive volunteers. Behavioural Pharmacology.2011;22(2):160-166. doi:10.1097/FBP.0b013e328343d 78a
47. Cubata WJ, Landowski J. Seizure following sudden zolpidem withdrawal. Progress in Neuro-Psychopharmacology and Biological Psychiatry.2007;31(2):539-540. doi:10.1016/j.pnpbp.2006.07.009
48. MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: The experience of zolpidem. Clinical Therapeutics.2014;36(11):1676-1701. doi:10.1016/j.cl inthera.2014.09.017
49. Farkas RH, Unger EF, Temple R. Zolpidem and driving impairment - Identifying persons at risk. New England Journal of Medicine.2013;369(8):689-691. doi:10.1056/NEJMp1307972
50. Greenblatt DJ, Harmatz JS, Roth T. Zolpidem and gender: Are women really at risk? Journal of Clinical Psychopharmacology.2019;39(3):189-199. doi:10.1097/JCP.0000000000001026
51. Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: Comparison with immediate-release standard zolpidem and placebo. Journal of Clinical Pharmacology.2006;46(12):1469-1480. doi:10.1177/0091270006293303
52. Cubata WJ, Landowski J, Wichowicz HM. Zolpidem abuse, dependence and withdrawal syndrome: Sex as susceptibility factor for adverse effects. British Journal of Clinical Pharmacology.2008;65(3):444-445. doi:10.1111/j.1365-2125.2007.03028.x
53. Wang LH, Lin HC, Lin CC, Chen YH, Lin HC. Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy. Clinical Pharmacology and Therapeutics.2010;88(3):369-374. doi:10.1038/clpt.2010.97
54. Carberry JC, Fisher LP, Grunstein RR, et al. Role of common hypnotics on the phenotypic causes of obstructive sleep apnoea: Paradoxical effects of zolpidem. The European respiratory journal. 2017;50(6). doi:10.1183/13993003.01344-2017